OR WAIT null SECS
© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
September 20, 2021
Investigators believe the use of biomarkers can determine the results of de-escalated neoadjuvant T-DM1 in HR-positive/HER2-positive early breast cancer.
Treatment with sunitinib resulted in improved efficacy results in the FIRSTMAPPP trial for patients with malignant pheochromocytoma and paraganglioma.
August 20, 2021
Dr. Christopher Lieu shares his insights into gaps in care in the adjuvant setting in colorectal cancer.
July 23, 2021
An expert in CRC describes key findings from clinical trials related to personalized detection of molecular recurrence in early stage CRC.
July 20, 2021
Javier L. Munoz, MD, MS, FACP, discusses how the sequencing of therapies has changed in the last year.
July 13, 2021
An expert in relapsed/refractory follicular lymphoma discusses the approval of tazemetostat as a treatment and reviews the phase 2 clinical trial data.
Javier L. Munoz, MD, MS, FACP, describes the current third-line treatment options available for relapsed/refractory follicular lymphoma.
July 12, 2021
Preliminary data from the phase 1b GO30103 study indicated that the combination of tiragolumab plus atezolizumab may have promise in patients with heavily pretreated metastatic esophageal cancer.
Dr. Lee Schwartzberg comments on unmet needs in the treatment of early-stage HR+ [hormone receptor-positive] breast cancer.
Current recommendations for conducting genomic testing in patients with HR+ [hormone receptor-positive] breast cancer, as outlined by the NCCN clinical practice guidelines.